ASX:RAD Radiopharm Theranostics (RAD) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free RAD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Radiopharm Theranostics alerts: Email Address Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Radiopharm Theranostics Stock (ASX:RAD)Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.Read More Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 RAD Stock News HeadlinesApril 10, 2024 | msn.comLisata wins FDA orphan drug status for bone cancer candidateApril 9, 2024 | msn.comRadiopharmaceutical emerges as the hottest space in biotech; here’s what it means for Clarity PharmaMarch 16, 2024 | morningstar.comRadiopharm Theranostics Ltd Ordinary SharesFebruary 25, 2024 | msn.comRadiopharmaceutical market expected to reach ~$14B by 2032February 13, 2024 | uk.finance.yahoo.comRadiopharm Theranostics Limited (RDPTF)February 5, 2024 | au.investing.comRadiopharm Theranostics' novel monoclonal antibody shows promise in cancer treatmentJanuary 26, 2024 | au.investing.comRadiopharm Theranostics completes entitlement offer shortfall for $1.7 millionJanuary 20, 2024 | morningstar.comRadiopharm Theranostics Ltd Ordinary Shares RADDecember 27, 2023 | au.investing.comRadiopharm Theranostics to open second Australian site for lung cancer trialDecember 22, 2023 | au.investing.comRadiopharm Theranostics launching Phase 1 lung cancer trials in JanuaryNovember 20, 2023 | au.investing.comRadiopharm Theranostics' $4.85 million R&D refund will support development of radiopharmaceutical productsOctober 30, 2023 | proactiveinvestors.com.auRadiopharm Theranostics launches $10 million entitlement offer to fund clinical trialsOctober 16, 2023 | proactiveinvestors.com.auRadiopharm Theranostics receives FDA greenlight to start Phase 1 imaging trial of RAD 301October 9, 2023 | finance.yahoo.comRAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung CancerOctober 9, 2023 | proactiveinvestors.com.auRadiopharm Theranostics secures approval for Phase 1 PDL1-nanobody non-small cell lung cancer studySeptember 1, 2023 | finance.yahoo.comRadiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)August 24, 2023 | finance.yahoo.comRadiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate CancerAugust 24, 2023 | proactiveinvestors.comRadiopharm Theranostics expands TerThera supply agreement for prostate cancer treatment trialJuly 24, 2023 | proactiveinvestors.com.auRadiopharm Theranostics appoints experienced radiopharmaceutical developer as VP Medical and Corporate AffairsJuly 23, 2023 | finance.yahoo.comTheradiag Reports Revenue of €6.7 Million for the First Half of 2023, up 6.8%July 19, 2023 | finance.yahoo.comIs Radiopharm Theranostics (ASX:RAD) In A Good Position To Invest In Growth?June 23, 2023 | marketwatch.comRadiopharmaceuticals Global Market is Projected to Reach $12.6 Billion by 2030: Innovative Radiopharmaceuticals to Boost Cardiac ApplicationsJune 9, 2023 | finance.yahoo.comDiamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023June 6, 2023 | proactiveinvestors.com.auRadiopharm Theranostics maintains A$0.70 valuation from Diamond Equity ResearchMay 31, 2023 | proactiveinvestors.com.auRadiopharm welcomes positive guidance from FDA to advance PivalateSee More Headlines Receive RAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Radiopharm Theranostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:RAD CUSIPN/A CIKN/A Webwww.riteaid.com Phone17177612633FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.05% Return on Assets-30.84% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio3.43 Sales & Book Value Annual Sales$6.01 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.06 per share Price / BookN/AMiscellaneous Outstanding Shares460,370,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.98 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)B.A (UNSW), FAICD, Founder & Executive Chairman Comp: $271.45kMr. Riccardo CanevariMD, CEO & DirectorMr. Vittorio Puppo M.D.Chief Operating OfficerProf. David MozleyChief Medical Officer & Scientific Advisory Board ChairDr. Thomas H. Tulip Ph.D. (Age 71)Chief Business Officer Comp: $504.74kMr. Phillip HainsCFO, Company Secretary & DirectorDr. Scot L. Harper Ph.D. (Age 67)Senior Vice President of Clinical Operations Mr. Bill ReganSenior Vice President of Regulatory StrategyDr. Rama Abu ShmeisSenior VP of Chemistry, Manufacturing & ControlsMr. Nathan Jong C.A.Company SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersRiccardo CanevariSold 2,128,815 sharesTotal: $223,525.58 ($0.11/share)Ian TurnerBought 99,980 shares on 8/3/2023Total: $9,898.02 ($0.10/share) This page (ASX:RAD) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.